VC
Velan Capital Investment Management LP
13F filer · CIK 0001848809Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$164MU.S. long equity reported on 13F
Positions506 new · 5 closed
Net flow last quarter-$6MBuys minus sells
Top 10 positions weight74.8%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202650 positions | |||||
| $29.7M | 18.10% | 0.32% | -11.9% | Q1 2023 | |
| $17.7M | 10.76% | 1.08% | Not reported | Q4 2025 | |
| $17M | 10.36% | 3.09% | Not reported | Q4 2024 | |
| $11.2M | 6.81% | 1.52% | +46.6% | Q2 2025 | |
| $10.9M | 6.62% | 4.81% | +0.4% | Q2 2024 | |
| $8.75M | 5.33% | 0.08% | -14.8% | Q3 2025 | |
| $8M | 4.87% | 1.72% | -5.7% | Q3 2024 | |
| $6.9M | 4.20% | 0.72% | Not reported | Q1 2026 | |
| $6.73M | 4.10% | 8.59% | Not reported | Q4 2022 | |
| $6M | 3.65% | 1.24% | +1.1% | Q4 2025 | |
| $6M | 3.65% | 0.61% | +75.3% | Q4 2024 | |
| $4.11M | 2.50% | 0.34% | +2.0% | Q1 2026 | |
| $3.9M | 2.38% | 0.78% | Not reported | Q4 2021 | |
| $3.74M | 2.28% | 4.62% | Not reported | Q4 2022 | |
| $2.89M | 1.76% | 2.75% | Not reported | Q4 2025 | |
| $2.66M | 1.62% | 0.46% | New | Q2 2026 | |
| $2.33M | 1.42% | 0.68% | Not reported | Q3 2025 | |
| $2.09M | 1.27% | 0.11% | Not reported | Q4 2021 | |
| $1.77M | 1.08% | 1.98% | New | Q2 2026 | |
| $1.48M | 0.90% | 0.45% | +2.9% | Q1 2026 | |
| $1.26M | 0.77% | 3.99% | Not reported | Q1 2026 | |
| $1.13M | 0.69% | 0.47% | -40.4% | Q4 2025 | |
| $1.12M | 0.68% | 9.50% | Not reported | Q4 2021 | |
| $454K | 0.28% | 0.01% | Not reported | Q2 2025 | |
| $450K | 0.27% | 0.06% | -77.8% | Q4 2024 | |
| $391K | 0.24% | 0.12% | +187.5% | Q1 2026 | |
| $388K | 0.24% | 0.02% | Not reported | Q4 2024 | |
| $350K | 0.21% | 0.07% | -18.8% | Q4 2024 | |
| $314K | 0.19% | 0.15% | Not reported | Q3 2025 | |
| $297K | 0.18% | 0.01% | Not reported | Q1 2025 | |
| $277K | 0.17% | 0.09% | +100.0% | Q1 2026 | |
| $244K | 0.15% | 0.14% | Not reported | Q3 2024 | |
| $243K | 0.15% | 0.10% | Not reported | Q1 2026 | |
| $221K | 0.13% | 0.02% | Not reported | Q4 2024 | |
| $219K | 0.13% | 0.01% | Not reported | Q3 2025 | |
| $212K | 0.13% | 0.01% | Not reported | Q1 2025 | |
| $206K | 0.13% | 0.03% | New | Q2 2026 | |
| $205K | 0.12% | 0.05% | -79.6% | Q1 2026 | |
| $195K | 0.12% | 0.09% | +33.3% | Q4 2024 | |
| $194K | 0.12% | 0.11% | New | Q2 2026 | |
| $184K | 0.11% | 0.01% | -89.0% | Q2 2025 | |
| $163K | 0.10% | 0.40% | New | Q2 2026 | |
| $157K | 0.10% | 0.05% | -61.9% | Q1 2026 | |
| $137K | 0.08% | 0.22% | Not reported | Q4 2025 | |
| $104K | 0.06% | 0.32% | -92.9% | Q2 2023 | |
| $102K | 0.06% | 0.11% | +38.9% | Q1 2026 | |
| $101K | 0.06% | 0.03% | Not reported | Q4 2024 | |
| $83.7K | 0.05% | 0.04% | Not reported | Q4 2024 | |
| $33.1K | 0.02% | 0.07% | -40.3% | Q2 2024 | |
| $11.5K | 0.01% | 0.01% | Not reported | Q3 2023 | |
| Q1 2026Reported May 15, 202649 positions | |||||
| $32.5M | 20.34% | 0.36% | Not reported | Q1 2023 | |
| $14.8M | 9.25% | 5.15% | Not reported | Q2 2024 | |
| $12.8M | 7.99% | 3.09% | +64.2% | Q4 2024 | |
| $10.3M | 6.43% | 1.24% | -11.9% | Q4 2025 | |
| $10M | 6.28% | 1.09% | -5.6% | Q4 2025 | |
| $9.33M | 5.84% | 2.40% | +600.0% | Q3 2024 | |
| $8.57M | 5.37% | 0.10% | +14.9% | Q3 2025 | |
| $7M | 4.39% | 4.64% | Not reported | Q4 2022 | |
| $6.74M | 4.22% | 1.40% | +2014.3% | Q2 2025 | |
| ETESPREsperion Therapeutics, Inc. | $4.71M | 2.95% | 0.67% | +42.2% | Q4 2025 |
| $4.33M | 2.71% | 9.31% | +20.4% | Q4 2022 | |
| $3.89M | 2.43% | 0.72% | New | Q1 2026 | |
| $3.42M | 2.14% | 4.48% | -2.1% | Q2 2023 | |
| $3.02M | 1.89% | 0.34% | New | Q1 2026 | |
| $2.76M | 1.73% | 0.75% | -29.8% | Q4 2024 | |
| $2.55M | 1.60% | 0.68% | Not reported | Q3 2025 | |
| $2.54M | 1.59% | 0.32% | +575.0% | Q4 2024 | |
| $2.49M | 1.56% | 2.75% | Not reported | Q4 2025 | |
| $2.34M | 1.46% | 9.53% | Not reported | Q4 2021 | |
| $2.29M | 1.43% | 0.78% | Not reported | Q4 2021 | |
| $2.05M | 1.28% | 0.44% | New | Q1 2026 | |
| $1.85M | 1.16% | 0.79% | Not reported | Q4 2025 | |
| $1.78M | 1.12% | 0.09% | +5.3% | Q2 2025 | |
| $1.05M | 0.66% | 0.27% | New | Q1 2026 | |
| $1.01M | 0.63% | 0.02% | -54.9% | Q4 2025 | |
| $798K | 0.50% | 3.99% | New | Q1 2026 | |
| $560K | 0.35% | 0.12% | New | Q1 2026 | |
| $408K | 0.26% | 0.00% | Not reported | Q3 2025 | |
| $390K | 0.24% | 0.01% | Not reported | Q2 2025 | |
| $355K | 0.22% | 0.10% | Not reported | Q4 2024 | |
| $298K | 0.19% | 0.01% | -92.7% | Q1 2025 | |
| $262K | 0.16% | 0.11% | Not reported | Q2 2024 | |
| $248K | 0.16% | 0.02% | Not reported | Q4 2024 | |
| $244K | 0.15% | 0.15% | +100.0% | Q3 2024 | |
| $234K | 0.15% | 0.01% | -92.3% | Q3 2025 | |
| $220K | 0.14% | 0.16% | +100.0% | Q3 2025 | |
| $219K | 0.14% | 0.01% | Not reported | Q1 2025 | |
| $213K | 0.13% | 0.03% | Not reported | Q1 2025 | |
| $161K | 0.10% | 0.10% | New | Q1 2026 | |
| $156K | 0.10% | 0.04% | New | Q1 2026 | |
| $153K | 0.10% | 0.02% | +33.3% | Q4 2024 | |
| $149K | 0.09% | 0.03% | Not reported | Q4 2024 | |
| $120K | 0.08% | 0.25% | +17.6% | Q4 2025 | |
| $104K | 0.07% | 0.08% | New | Q1 2026 | |
| $90.5K | 0.06% | 0.14% | +108.6% | Q4 2024 | |
| $86.7K | 0.05% | 0.05% | New | Q1 2026 | |
| $83.6K | 0.05% | 0.07% | Not reported | Q4 2024 | |
| $72.9K | 0.05% | 0.04% | Not reported | Q4 2024 | |
| $23K | 0.01% | 0.03% | Not reported | Q3 2023 | |
| Q4 2025Reported Feb 13, 202645 positions | |||||
| $29.7M | 17.23% | 0.40% | -24.1% | Q1 2023 | |
| CTCDTXCidara Therapeutics, Inc. | $23.9M | 13.89% | 0.34% | Not reported | Q2 2025 |
| $15.1M | 8.76% | 5.29% | +32.5% | Q2 2024 | |
| $11.4M | 6.60% | 4.65% | Not reported | Q4 2022 | |
| $9.17M | 5.32% | 1.19% | New | Q4 2025 | |
| $9.04M | 5.24% | 0.09% | +4.1% | Q3 2025 | |
| $8.68M | 5.03% | 1.61% | New | Q4 2025 | |
| $5.48M | 3.18% | 0.19% | -14.0% | Q1 2025 | |
| $4.97M | 2.88% | 0.12% | +1.6% | Q4 2021 | |
| $4.88M | 2.83% | 9.53% | Not reported | Q4 2021 | |
| $4.79M | 2.78% | 1.42% | Not reported | Q4 2024 | |
| ETESPREsperion Therapeutics, Inc. | $4.48M | 2.60% | 0.51% | New | Q4 2025 |
| $3.92M | 2.27% | 2.75% | New | Q4 2025 | |
| $3.82M | 2.21% | 4.92% | Not reported | Q2 2023 | |
| RTRAPTRAPT Therapeutics, Inc. | $3.66M | 2.12% | 0.39% | +35.0% | Q4 2021 |
| $3.61M | 2.09% | 3.63% | Not reported | Q4 2024 | |
| TPTERNTerns Pharmaceuticals, Inc. | $2.83M | 1.64% | 0.06% | +250.0% | Q4 2022 |
| $2.73M | 1.58% | 0.15% | Not reported | Q3 2025 | |
| $2.69M | 1.56% | 0.08% | Not reported | Q2 2025 | |
| $2.66M | 1.54% | 0.68% | Not reported | Q3 2025 | |
| $2.57M | 1.49% | 0.16% | Not reported | Q3 2025 | |
| $2.25M | 1.30% | 0.79% | New | Q4 2025 | |
| $2.07M | 1.20% | 0.04% | New | Q4 2025 | |
| $1.77M | 1.03% | 0.78% | Not reported | Q4 2021 | |
| $1.02M | 0.59% | 0.89% | Not reported | Q3 2024 | |
| $976K | 0.57% | 8.25% | Not reported | Q4 2022 | |
| $432K | 0.25% | 0.00% | Not reported | Q3 2025 | |
| VBVTYXVentyx Biosciences, Inc. | $361K | 0.21% | 0.06% | Not reported | Q4 2024 |
| $341K | 0.20% | 0.05% | Not reported | Q4 2024 | |
| $323K | 0.19% | 0.01% | Not reported | Q2 2025 | |
| $304K | 0.18% | 0.02% | Not reported | Q4 2024 | |
| $261K | 0.15% | 0.12% | Not reported | Q4 2024 | |
| $217K | 0.13% | 0.03% | Not reported | Q3 2023 | |
| $215K | 0.12% | 0.01% | Not reported | Q1 2025 | |
| $188K | 0.11% | 0.03% | Not reported | Q1 2025 | |
| $183K | 0.11% | 0.07% | Not reported | Q2 2025 | |
| $147K | 0.09% | 0.11% | Not reported | Q2 2024 | |
| $146K | 0.08% | 0.02% | -25.0% | Q4 2024 | |
| $126K | 0.07% | 0.04% | Not reported | Q4 2024 | |
| $109K | 0.06% | 3.75% | New | Q4 2025 | |
| $106K | 0.06% | 0.07% | -78.7% | Q3 2024 | |
| $90.9K | 0.05% | 0.04% | Not reported | Q4 2024 | |
| $83.2K | 0.05% | 0.08% | Not reported | Q3 2025 | |
| $46K | 0.03% | 0.06% | -27.3% | Q2 2025 | |
| $43.8K | 0.03% | 0.07% | Not reported | Q4 2024 | |
| Q3 2025Reported Nov 14, 202549 positions | |||||
| $11M | 10.36% | 5.71% | +25.3% | Q4 2022 | |
| CTCDTXCidara Therapeutics, Inc. | $10.4M | 9.75% | 0.37% | +8.4% | Q2 2025 |
| $9.3M | 8.74% | 5.54% | Not reported | Q2 2024 | |
| $7.05M | 6.62% | 0.82% | Not reported | Q4 2021 | |
| $7.04M | 6.61% | 0.63% | -11.1% | Q1 2023 | |
| $6.66M | 6.25% | 0.22% | +0.6% | Q1 2025 | |
| $6.21M | 5.83% | 9.54% | +86.1% | Q4 2021 | |
| $5.47M | 5.13% | 0.10% | New | Q3 2025 | |
| $5.17M | 4.85% | 5.11% | +137.1% | Q2 2023 | |
| $4.28M | 4.02% | 16.47% | New | Q3 2025 | |
| $3.78M | 3.55% | Not reported | -41.6% | Q2 2025 | |
| $3.77M | 3.54% | 0.10% | Not reported | Q4 2021 | |
| $3.35M | 3.15% | 1.48% | +70.1% | Q4 2024 | |
| $2.71M | 2.54% | 3.67% | +2.0% | Q4 2024 | |
| $2.08M | 1.95% | 0.99% | New | Q3 2025 | |
| RTRAPTRAPT Therapeutics, Inc. | $2.06M | 1.94% | 0.48% | Not reported | Q4 2021 |
| $2M | 1.88% | 0.15% | New | Q3 2025 | |
| $1.88M | 1.76% | 0.16% | New | Q3 2025 | |
| $1.87M | 1.75% | 0.05% | New | Q3 2025 | |
| $1.87M | 1.75% | 0.11% | Not reported | Q2 2025 | |
| $1.7M | 1.60% | 9.63% | Not reported | Q4 2022 | |
| $1.11M | 1.05% | 1.85% | Not reported | Q4 2021 | |
| $899K | 0.84% | 0.58% | +2.4% | Q4 2024 | |
| $772K | 0.72% | 0.49% | +3.4% | Q3 2024 | |
| $634K | 0.60% | 1.41% | Not reported | Q3 2024 | |
| TBTRMLTourmaline Bio, Inc. | $277K | 0.26% | 0.02% | -98.5% | Q4 2023 |
| $255K | 0.24% | 0.05% | +6.7% | Q4 2024 | |
| $246K | 0.23% | 0.01% | Not reported | Q2 2025 | |
| $224K | 0.21% | 0.00% | New | Q3 2025 | |
| $208K | 0.20% | 0.22% | Not reported | Q4 2024 | |
| $184K | 0.17% | 0.03% | -6.7% | Q3 2023 | |
| $163K | 0.15% | 0.05% | Not reported | Q4 2024 | |
| $151K | 0.14% | 0.04% | Not reported | Q1 2025 | |
| TPTERNTerns Pharmaceuticals, Inc. | $150K | 0.14% | 0.02% | Not reported | Q4 2022 |
| $148K | 0.14% | 0.02% | +60.0% | Q4 2024 | |
| $142K | 0.13% | 0.02% | Not reported | Q1 2025 | |
| VBVTYXVentyx Biosciences, Inc. | $124K | 0.12% | 0.06% | Not reported | Q4 2024 |
| $122K | 0.11% | 0.09% | +37.5% | Q2 2025 | |
| $117K | 0.11% | 0.01% | Not reported | Q1 2025 | |
| $110K | 0.10% | 0.17% | New | Q3 2025 | |
| $110K | 0.10% | 0.01% | Not reported | Q4 2024 | |
| $110K | 0.10% | 0.01% | +14.3% | Q1 2023 | |
| $107K | 0.10% | 0.04% | Not reported | Q4 2024 | |
| $96.9K | 0.09% | 0.11% | Not reported | Q2 2024 | |
| $95.9K | 0.09% | 0.04% | Not reported | Q4 2024 | |
| $83.8K | 0.08% | 0.03% | -89.1% | Q4 2024 | |
| $73.2K | 0.07% | 0.11% | +40.0% | Q2 2025 | |
| $62.1K | 0.06% | 0.03% | Not reported | Q4 2023 | |
| $49K | 0.05% | 0.07% | Not reported | Q4 2024 | |
Premium opens every quarter this fund has filed